Aprotinin, but not ε-aminocaproic acid and tranexamic acid, exerts neuroprotection against excitotoxic injury in an in vitro neuronal cell culture model  by Lu, Zhaohui et al.
Lu et al Evolving Technology/Basic ScienceAprotinin, but not ε-aminocaproic acid and tranexamic acid, exerts
neuroprotection against excitotoxic injury in an in vitro neuronal cell
culture modelZhaohui Lu, MD,a,c Ludmila Korotcova, MD,a,b Akira Murata, MD,a,b Nobuyuki Ishibashi, MD,a,b and
Richard A. Jonas, MDa,bFrom C
Child
and
China
This stu
Jonas
Disclos
N.I. and
Receive
for pu
Address
Mich
0022-52
Copyrig
http://dxObjective: Lack of availability of aprotinin has resulted in increased clinical use of the alternative antifibrino-
lytic agents, ε-aminocaproic acid (EACA) and tranexamic acid (TXA), which are known to be associated with an
increased risk of seizures. In contrast, aprotinin has previously been demonstrated to be neuroprotective through
suppression of excitotoxicity-mediated neuronal degeneration via the extracellular plasminogen/plasmin sys-
tem. This study compares the effect of antifibrinolytic agents on neuronal and mixed glial/neuronal cell cultures.
Methods:Mixed cortical cultures containing neuronal and glial cells were prepared from fetal mice and plated
on a layer of confluent astrocytes from postnatal pups. A primary neuronal culture was obtained from the same
gestational stage and plated in multiwall vessels. Slowly triggered excitotoxicity was induced by 24-hour expo-
sure to 12.5 mM N-methyl-D-aspartate (NMDA). Apoptotic neuronal cell death was induced by exposure of pri-
mary neural cultures to 24 hours of serum deprivation.
Results: Compared with NMDA alone, no significant changes in cell death were observed for any dose of TXA
or EACA inmixed cultures. Conversely, a clinical dose of aprotinin significantly reduced cell death by31% on
average. Aprotinin reduced apoptotic neuronal cell death from 75% to 37.3%, and to 34.1% at concentrations of
100 and 200 kIU/mL, respectively, and significantly decreased neuronal nuclear damage. These concentrations
of aprotinin significantly inhibited caspase 9 and 3/7 activations; 250 kIU/mL aprotinin exerted maximal pro-
tection on primary cortical neurons.
Conclusions: In contrast to aprotinin, EACA and TXA exert no protective effect against excitotoxic neuronal
injury that can occur during cardiac surgery. (J Thorac Cardiovasc Surg 2014;147:1939-45)/B
SLow-flow cardiopulmonary bypass and deep hypothermic
circulatory arrest are used to facilitate pediatric cardiac sur-
gery although they carry a risk of ischemic brain damage.
One mechanism of ischemic neuronal cell death is glutama-
tergic excitotoxcity.1 Initially, an ischemic insult impairs
glutamate transport at the postsynaptic level resulting in
high extracellular levels of glutamate1,2 resulting in
excessive calcium influx and eventually leading to
neuronal cell death.1
Studies of excitotoxicity-mediated neuronal degenera-
tion have identified the extracellular plasminogen/plasmin
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Tthrough activation of intrinsic tissue-plasminogen acti-
vator.3,4 Aprotinin, which is used as an antifibrinolytic
agent during cardiac surgery, inhibits plasminogen
activation. We previously demonstrated that aprotinin
has neuroprotective effects against glutamatergic
excitotoxicity.5 It also protects endothelial function in the
brain.6 Lysine analogs such as ε-aminocaproic acid
(EACA) and tranexamic acid (TXA) block the binding of
plasminogen to fibrin and plasminogen activation and trans-
formation to plasmin.7 The lysine analogs, therefore, also
have the potential to provide neuroprotection through their
inhibition of plasminogen activation.
In the present study, a neuronal cell culture model was
used to examine whether antifibrinolytic lysine analogs
are also neuroprotective against glutamatergic excitotoxic-
ity. The antiapoptotic effects of aprotinin were then as-
sessed. The mechanisms underlying the neuroprotective
effects of aprotinin were studied and the optimal dose for
clinical application during cardiac surgery was investigated.METHODS
Primary Cortical Neuron Cultures
Primary cortical neuron cultures containing less than 5% astrocytes
were obtained from fetal mice at 13 to 15 days’ gestation (Charles River,
Germantown, Md). Dissociated cortical cells in plating medium of mediadiovascular Surgery c Volume 147, Number 6 1939
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
DIV ¼ days in vitro
DMEM ¼ Dulbecco’s modified Eagle’s medium
EACA ¼ ε-aminocaproic acid
FITC ¼ fluorescein isothiocyanate
GABAA ¼ g-aminobutyric acid type A
LDH ¼ lactate dehydrogenase
MS ¼ media stock
MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide
NMDA ¼ N-methyl-D-aspartate
RLU ¼ relative light units
SD ¼ serum deprivation
TXA ¼ tranexamic acid
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Sstock (MS; Dulbecco’s modified Eagle’s medium [DMEM] with 25 mM
glucose; Sigma, St. Louis, Mo) supplemented with 5% fetal bovine serum
(Gibco, Carlsbad, Calif), 5% horse serum (Gibco, Carlsbad, Calif) and 2
mM glutamine (Sigma, St. Louis, Mo) were plated in 24-well plates coated
with poly-D-lysine (0.1 mg/dL; Invitrogen, Carlsbad, Calif) and laminin
(0.02 mg/mL; Invitrogen, Carlsbad, Calif). After 3 days in vitro (DIV),
nonneuronal cell division was halted by exposure to 10 mM cytosine arabi-
noside (Ara-C; Sigma, St. Louis, Mo). There was no further exchange of
medium except the addition of DMEM for evaporation. All cultures were
kept at 37C in a humidified 5% CO2 incubator. Cultures were used after
7 DIV for serum deprivation (SD). All experiments were performed in
compliance with the National Institutes for Health Guide for the Care
and Use of Laboratory Animals. The study was approved by the Institu-
tional Animal Care and Use Committee of the Children’s National Medical
Center.
Glial Cell Cultures
Glial cell cultures were prepared from postnatal mice at 1 to 3 days old
(Swiss Webster mice; Charles River, Germantown, Md). Dissociated
cortical cells were plated in 24-well plates previously coated with poly-
D-lysine using a plating medium of MS supplemented with 10% horse
serum, 10% fetal bovine serum (Gibco, Carlsbad, Calif), and 2 mmol/L
glutamine. Cultures were kept at 37C in a humidified atmosphere contain-
ing 5% CO2 until they reached confluence 7 to 14 DIV. Confluent cultures
were then used as a support for mixed cultures.
Mixed Cortical Cultures
Mixed cortical cultures containing both neurons and astrocytes were
prepared from fetal mice at 14.5 days’ gestation. Dissociated cortical cells
were plated in 24 wells on a layer of confluent astrocytes, usingMS supple-
mented with 5% horse serum, 5% fetal bovine serum, and 2 mmol/L gluta-
mine. After 7 DIV, nonneuronal cell division was halted by 3 days of
exposure to 10 mM Ara-C. Subsequent partial medium replacement was
performed twice per week, and after 12 DIV, cultures were shifted to a
maintenance medium identical to the plating medium but lacking serum,
because neurons survive without it. Experiments were performed on
cortical cultures after 13 to 14 DIV.
Excitotoxicity
Slowly triggered excitotoxicity was induced at 37C by 24-hour expo-
sure to 12.5 mM N-methyl-D-aspartic acid (NMDA) as an excitotoxin in
medium stock supplemented with 10 mM glycine. TXA, EACA, or1940 The Journal of Thoracic and Cardiovascular Suraprotinin was coapplied at 3 different concentrations (low dose, clinical
dose, high dose) with the excitotoxin and left for 24 hours in the bathing
medium. The clinical therapeutic concentration of each agent is 0.8 mM
for TXA, 1 mM for EACA,8 and 250 kIU/mL for aprotinin.9 Low and
high dose were one-third and 3 times the clinical dose, respectively. It
has been recommended the plasma TXA concentration should be main-
tained at more than 0.8 mM for patients at high risk of bleeding,10 therefore
we chose 0.8 mM as the clinical therapeutic concentration of TXA in this
study, which corresponds with the recommended dose of TXA 100 mg/kg
as a single bolus before surgery or a medical regimen with a loading dose of
30 mg/kg plus additional 2 mg/kg added to the pump prime followed by 16
mg/kg/h infusion in adult patients.10
Neuronal death resulting from slowly triggered excitotoxicity was
confirmed by examining cultures under phase-contrast microscopy and
quantified by measurement of lactate dehydrogenase (LDH) release from
damaged cells into the bathing medium 1 day after the onset of excitotoxin
exposure. LDH was measured by an enzyme-linked immunosorbent assay
kit (Promega, Madison, Wis). The LDH level corresponding to complete
neuronal death was determined in sister cultures exposed to 100 mM
NMDA. Background LDH levels were determined in sister cultures with
sham wash as a control and subtracted from experimental values to yield
the signal specific to experimentally induced injury.
Serum Deprivation
Apoptosis was induced by SD for 24 hours at 7 DIVas described previ-
ously.4 In brief, each cell culture was rinsed; then, aprotinin at tested con-
centrations was applied to the culture medium without any serum. One
group was treated with normal neurobasal medium after the rinse as con-
trol, and another was treated with DMEMwithout any serum and aprotinin.
Secondary NMDA receptor activation was blocked by the addition of MK-
801 to the medium at a final concentration of 10 mM. Plates were then incu-
bated for 24 hours.
Trypan Blue Staining
Trypan Blue, a vital stain used to selectively color dead tissue or cells
blue, was used to differentiate live neurons from dead neurons. After the
induction of apoptosis by SD, 100 mL of Trypan Blue prewarmed to
37C were added to each well, and the cells were incubated at 37C for
15 minutes. The cells were then fixed in phosphate-buffered formalin solu-
tion (4%) for 30 minutes at room temperature. Neurons in each dish were
counted in 7 different areas using an inverted microscope. Unstained neu-
rons with intact soma and neurites were regarded as viable, and dark-
stained neurons were considered damaged. Cell counting was performed
in a blinded fashion.
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide Assay
Viability of neurons was assessed using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, 30 mL of MTT
were added to each well and incubated at 37C for 3 hours. The supernatant
medium was gently removed and cells were solubilized with 250 mL of di-
methylsulfoxide. Then, 100 mL of medium was transferred to a 96-well
plate and formazan reduction was detected by measuring absorbance at
570 nm (OD570) with a reference wavelength of 655 nm in a
spectrophotometer.
Hoechst Staining
The Hoechst stains belong to a family of fluorescent stains that label
DNA by fluorescence. Because these fluorescent stains label DNA, they
are also commonly used to visualize nuclei and mitochondria.11 Briefly,
primary cortical neurons that had been treated as mentioned earlier were
fixed in 4% paraformaldehyde for 20 minutes, and were then stained
with 20 mg/mLHoechst 33258 dye for 10minutes, followed by observationgery c June 2014
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sion was filtered with a 510-nm barrier filter. Neurons with fragmented or
condensed DNA or with normal DNA were counted to quantify the
apoptotic process. Data are expressed as the ratio of apoptotic neurons to
total neurons.
Flow Cytometry
Neuronal apoptosis was assayed by flow cytometry using an annexin
V/fluorescein isothiocyanate (FITC) kit (Molecular Probes, Eugene,
Ore), as described previously.12 After 24 hours of SD, cells were washed
twice with cold phosphate-buffered saline and were detached from the
bottom with trypsin-EDTA treatment for 2 to 10 minutes at 37C. After
adding phosphate-buffered saline with 2% fetal bovine serum, neurons
were harvested and centrifuged at 1500 rpm for 5 minutes. Neurons were
resuspended in 13 binding buffer (10 mM HEPES, 140 mM NaCl,
2.5 mM CaCl2) at a concentration of 1 3 10
6 cells/mL. One hundred
microliters of each cell suspension was transferred to a 5-mL tube and
5 mL of FITC-conjugated annexin V and propidium iodide (PI)
(50 mg/mL) were added. After 15 minutes incubation in the dark at room
temperature, 400 mL of binding buffer were added to each tube and cells
were analyzed for annexin V binding within 1 hour with a flow cytometer.
Caspase 3/7 and 9 Assays
Caspase activity was detected using caspase 9 and 3/7 assay kits (Prom-
ega, Madison, Wis) as per the manufacturer’s protocol. Caspase 3/7 and 9
concentrations were expressed as relative light units (RLU) per milligram
of cellular protein measured with a Reporter microplate luminometer
(Promega, Madison, Wis). The background luminescence associated with
the cell culture and assay reagent (blank reaction) was subtracted from
the experimental values. The activities of caspases 3/7 and 9 were reported
as the means of experiments conducted in triplicate.
Immunohistochemistry
To identify caspase 3-positive neural cells after 24 hours SD, cultured
neurons were immunolabeled with a primary antibody to caspase3 (Cell
Signaling Technology, Danvers, Mass) diluted in 0.1 M phosphate-
buffered saline (pH 7.4) containing 0.1% Triton X-100 and 5% normal
goat serum for 1 hour at 4C. Cells were then carefully washed in medium
and incubated in the secondary antibody for 1 hour at 4C, and mounted on
slides. For cell counting, images were captured using a fluorescence micro-
scope. Samples were then analyzed using ImageJ software (available at
http://rsbweb.nih.gov/ij/index.html). To determine cell density, the anti-
body positive cells were quantified in 5 microscopic fields from each sam-
ple (6 samples per group) in a blinded fashion.
Statistics
One-way analysis of variance (ANOVA) with Bonferroni post hoc com-
parisons was used to detect differences in each analysis between tested
groups. Analysis of the data was performed using SPSS version 19.0
(SPSS Inc/IBM, Chicago, Ill).RESULTS
Aprotinin, but Not Lysine Analogs, Are
Neuroprotective Against Glutamatergic
Excitotoxicity
Sham wash and the addition of 2 lysine analogs and apro-
tinin alone at high dose did not influence neuronal cells in
either culture (Figure 1, A-D). Excitotoxicity induced by
exposure of the cultures to 12.5 mMNMDA for 24 hours re-
sulted in acute swelling of neuronal cell bodies, followed byThe Journal of Thoracic and Carwidespread necrotic neuronal degeneration resulting in dis-
rupted neurons and segmentalized neurites (Figure 1, E).
When EACA and TXA were coapplied in the medium
with the excitotoxin, both lysine analogs did not preserve
neuronal cells and neurites (Figure 1, F andG). On the other
hand, the damage was significantly reduced under the con-
dition with aprotinin (Figure 1, H). Exposure to 12.5 mM
NMDA caused approximately 70% neuronal cell death
(Figure 1, I). There were no effects on cell death with any
dose of TXA or EACA (Figure 1, I). In contrast, aprotinin
reduced neuronal death in a dose-dependent fashion
(Figure 1, I). Compared with NMDA alone, no significant
changes in cell death were observed for clinical doses of
TXA or EACA, whereas aprotinin significantly reduced
cell death by 31% on average (Figure 1, J). The results
indicate that, among major antifibrinolytic agents used clin-
ically in cardiac surgery, only aprotinin has a neuroprotec-
tive effect against excitotoxic brain injury.
Aprotinin Prevents SD-Induced Apoptosis in Cortical
Neurons
In addition to the effect of aprotinin against glutamatergic
excitotoxicity, our previous results suggested a potential anti-
apoptotic effect.13 In the present study using primary cortical
neuronal cultures, 100 and 200 kIU/mL aprotinin signifi-
cantly decreased the percentage of cells positive with Trypan
Blue resulting from SD-induced apoptosis,4,14 compared
with the control (Figure 2, A). Consistent with these results,
cell viability using the MTT assay significantly decreased at
24 hours after SD in the no aprotinin group; 100 kIU/mL and
200 kIU/mL aprotinin significantly increased the viability
compared with no aprotinin (Figure 2, B). When Hoechst
33258 staining was performed at the same time point and
damaged cells were characterized by condensed chromatin,
reduced nuclear size, and nuclear fragmentation (Figure 2,
C-G), it was identified that the percentage of damaged cells
significantly decreased in 100 and 200 kIU/mL aprotinin
(25.0%  3.8% and 20.3%  3.6%, respectively)
compared with no aprotinin (34.0% 4.7%; P<.01). How-
ever, there were no significant differences between 50 kIU/
mL and no aprotinin in assessments using Trypan Blue,
MTT, and Hoechst 33258 (Figure 2, A, B, and E). The per-
centage of early apoptotic neurons identified by annexin
Vþ using flow cytometry was not significantly different be-
tween aprotinin and no aprotinin treatment after 24 hours
SD. When advanced apoptosis was indicated by annexin
Vþ and V/PIþ, 78.8% of neurons (10.4%) were identified
as having undergone advanced apoptosis; this effect was
significantly reduced by aprotinin at all 3 concentrations
tested (50 kIU/mL aprotinin, 46.1%  12.0%; 100 kIU/
mL, 37.1%  14.3%; 200 kIU/mL, 43.5%  21.3%;
P< .01). These findings demonstrate that, in addition to a
neuroprotective effect against excitotoxicity, aprotinin signif-
icantly inhibits apoptosis in cortical neurons.diovascular Surgery c Volume 147, Number 6 1941
FIGURE 1. Aprotinin, but not lysine analogs, are neuroprotective against glutamatergic excitotoxicity. A-D, Mixed cortical culture at 24 hours after Sham
wash (A), and Sham wash with clinical dose TXA (B) EACA (C) and aprotinin (D). E-H, Mixed cortical culture after 24-hour exposure with 12.5 mM
NMDA (E), and 12.5 mM NMDA with clinical dose TXA (F) EACA (G) and aprotinin (H). I, Percentage of cell death at 24 hours after 12.5 mM
NMDA exposure with TXA, EACA, and aprotinin. Neural cell death was identified by LDH assay measuring LDH levels in bathing medium in cultures.4
Low, clinical, and high doses of aprotinin reduced neuronal death from 70% to 56%, 39%, and 31%, respectively (F¼ 104.6, P<.0001). J, Percentage cell
death at 24 hours after 12.5 mM NMDA exposure with clinical doses of TXA, EACA, and aprotinin compared with 12.5 mMNMDA alone. There were no
significant changes in TXA (þ8%, P¼ .11) and EACA (3%, P¼ .45). A clinical dose of aprotinin significantly reduced cell death by31% on average
(P<.0001). *P<.001 versus 12.5 mMNMDA by ANOVAwith Bonferroni comparisons. Data are shown as means standard error of the mean (n ¼ 12).
NMDA, N-Methyl-D-aspartic acid; EACA, ε-aminocaproic acid; TXA, tranexamic acid.
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Pathway and 250 kIU/mL is an Optimal Dose for
Protection
To identify a pathway involving aprotinin-induced inhi-
bition of apoptosis, caspase 3/7 and 9 levels were assessed
after 24 hours SD. Aprotinin significantly decreased the
level of caspase 3/7 in a dose-dependent manner
(Figure 3, A). This dose-dependent change correlated with
apoptotic neural injury identified by Trypan Blue and
MTT assays (Figure 2, A and B), suggesting that a
caspase-dependent mechanism includes an antiapoptotic
effect due to aprotinin. It was also identified that caspase
9 activity was significantly inhibited by 100 and 200
kIU/mL aprotinin (Figure 3, B). When apoptosis was1942 The Journal of Thoracic and Cardiovascular Surinduced by 200 nM staurosporin, however, there were no
significant differences in the MTTassay between any doses
of aprotinin (data not shown). It is known that staurosporin
induces apoptosis through both caspase-dependent and -in-
dependent mechanisms15; SD induces apoptotic cell death
using a caspase-dependent mechanism via a mitochondrial
pathway.16 Therefore, it is likely that inhibition of apoptosis
by aprotinin occurs by a caspase-dependent mechanism
through the mitochondrial pathway.
The antiapoptotic effect of aprotinin was assessed from
100 kIU/mL up to 1000 kIU/mL to identify the optimal
dose for adjunctive neuroprotection. Using immunohisto-
chemistry, 100 and 250 kIU/mL aprotinin dose-
dependently decreased caspase 3þ cell percentages aftergery c June 2014
FIGURE 2. Aprotinin prevents serum deprivation (SD)–induced apoptosis in cortical neurons. A, Percentage of Trypan Blue positive cells at 24 hours after
SD. Ten percent cell death in the control supports a technical consistency in our study.35 Aprotinin at 50, 100 and 200 kIU/mL decreased the percentage of
Trypan Blue positive cells from 75% to 60%, 37% and 34%, respectively. B, Cell viability using theMTTassay after 24 hours SD. Aprotinin at 100 and 200
kIU/mL significantly increased the viability compared with no aprotinin (P<.05). There was no significant difference between no aprotinin and 50 kIU/mL
aprotinin. C-G, Images with Hoechst 33258 staining at 24 hours after sham wash (C) and after SD with aprotinin at the concentration of 0 (D), 50 (E), 100
(F), and 250 kIU/mL (G). *P<.05, **P<.01, ***P<.001 versus aprotinin 0 kIU/mL by ANOVAwith Bonferroni comparisons. Data are shown as means
standard error of the mean (n ¼ 8). AP, Aprotinin.
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500 and 1000 kIU/mL also reduced the percentage
compared with no aprotinin; however, these doses did not
provide significant reduction compared with 250 kIU/mL
(Figure 3, C). This suggests that approximately 200 to
250 kIU/mL is an optimal dose of aprotinin for adjunctive
protection during cardiac surgery.
DISCUSSION
This study is the first to describe the neuroprotective
potential of 3 antifibrinolytic agents used during cardiac
surgery against glutamatergic excitotoxicity in mixed
cortical cell culture models. The antiapoptotic effects of
aprotinin were demonstrated using various analyses in a pri-
mary neuronal cell culture system. The optimal dose for
neuroprotection in clinical applications during cardiac sur-
gery was identified.
Recently, there has been increasing interest in the role of
antifibrinolytic agents in postoperative neurologic events.
High-dose TXA has been identified as an independent
predictor of early seizures after cardiopulmonary bipass in
clinical studies.17,18 A retrospective data analysis has also
demonstrated that even moderate doses of TXA are
associated with double the rate of convulsive seizures and
in-hospital mortality.19 Consistent with these findings, a
preclinical study by Lecker and colleagues20 identified
that the reduction in function of glycine receptors caused
by TXA leads to disinhibition and proconvulsive effects.
Because their results and those of others21 determined
that TXA is a competitive antagonist of g-aminobutyric
acid type A (GABAA) receptors, it is suggested that TXA
inhibition of GABAA receptors increases network excit-
ability.20 EACA is also a competitive antagonist of glycine
receptors, but not aprotinin.20 The present study investi-
gated the neuroprotective potential of antifibrinolytic agentsThe Journal of Thoracic and Caragainst glutamatergic excitotoxicity, which is a major
mechanism of ischemic neuronal cell death. An in vitro cul-
ture model was used, but electrophysiologic activity was
not studied. However, an ex vivo rodent brain slice model
has recently been developed replicating specific brain con-
ditions of deep hypothermic circulatory arrest including
ischemia-reperfusion/reoxygenation under hypothermia.22
Receptor expression and function on neurons and glial cells
are dynamically changing during development23; however,
there is little information regarding the effects of pharmaco-
logic reagents including antifibrinolytics during cardiac
surgery on electrophysiologic activity in the developing
brain. Rodent brain slice models have been used extensively
for electrophysiologic studies and for the development of
pharmacologic therapy. Thus, the model will be useful for
the study of optimal antifibrinolytic agents in pediatric car-
diac surgery. Future studies using the in vitro neuronal cell
culture model, ex vivo brain slice model, and in vivo large
animal model will provide novel insights regarding cellular
and molecular mechanisms underlying neurologic deficits
after cardiac surgery, and allow for the design of targeted
therapies and conditions that will minimize the risk of neu-
rodevelopmental deficits in patients with congenital heart
disease.
In 2007, the US Food and Drug Administration suggested
to the Bayer Corporation that it should suspend marketing
of aprotinin following a retrospective propensity match
review by Mangano and colleagues24 and preliminary anal-
ysis of a prospective trial in Canada (BART trial).25 The
Bayer Corporation responded by voluntarily removing all
remaining stocks of aprotinin from the US market in
2008.25 However, evidence has been accumulating on the
deleterious effects of alternative hemostatic agents such as
Factor VII and lysine analogs as well as the disadvantages
of massive transfusion, suggesting that the protective effectsdiovascular Surgery c Volume 147, Number 6 1943
FIGURE 3. Aprotinin inhibits apoptosis via the mitochondrial pathway and 250 kIU/mL is an optimal dose for protection. A and B, Caspase 3/7 and 9
activity after 24 hours serum deprivation (SD) in primary cortical neuron culture. C-E, Images after 24 hours SD in a neuron culture without aprotinin.
F, Percentage of caspase 3–positive cells at 24 hours after SD with aprotinin at the concentration of 0, 100, 250, 500, and 1000 kIU/mL. *P< .05,
**P<.01, ***P<.001 versus aprotinin 0 kIU/mL by ANOVA with Bonferroni comparisons. Data are shown as means  standard error of the mean
(n ¼ 6-8). AP, Aprotinin.
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subsequent analysis of the BART trial, Health Canada
concluded in 2011 that the trial could not be reliably used
to assess the benefit-risk balance of aprotinin as a result
of study weaknesses.29 The European Medicines Agency
also released a statement in 2012 indicating that the benefits
of aprotinin outweigh its risks in patients and recommended
to the European Union that the suspension of the license for
aprotinin in this context be lifted.29
In addition to functioning as an important hemostatic
agent, it has been suggested that aprotinin inhibits nitric ox-
ide synthase activity30 and the proinflammatory activation
of endothelial cells.31 Using both a piglet model involving
cardiopulmonary bypass as well as a neuronal cell culture
model, abundant evidence for the neuroprotective effects
of aprotinin is available.5,6,32-34 Thus, it can be inferred
that aprotinin is the preferred antifibrinolytic agent during
cardiac surgery, in particular for patients at high risk of
procedure-related brain injury, such as those undergoing
circulatory arrest. It is likely that aprotinin will be reintro-
duced into the United States through a distributor other
than the Bayer Corporation. This will allow clinical trials1944 The Journal of Thoracic and Cardiovascular Surto explore the neuroprotective effects of aprotinin as studied
in this report.CONCLUSIONS
Aprotinin at 200 to 250 kIU/mL exerts maximal protec-
tive effects on primary cortical neurons cultured in vitro.
This effect might result from caspase-dependent and/or
-independent pathways. In conjunction with our previous
studies, aprotinin is a multipotent serine protease inhibitor
that can protect the brain during cardiac surgery.
The authors thank Dr David Zurakowski for assistance with sta-
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